Israel’s Endospan (see here previously) shared good early news from the trial on 22 patients of its Nexus Aortic Arch Stent Graft System. The trial is being extended to 110 patients. 120,000+ patients suffer thoracic aortic arch disease every year … Continue reading →

Israel’s Endospan (reported here previously) has been granted Breakthrough Device Designation from the U.S. FDA for its NEXUS Aortic Arch Stent Graft System.  It already has the CE Mark of European approval. https://www.businesswire.com/news/home/20200419005001/en/FDA-Grants-NEXUS%E2%84%A2-Aortic-Arch-Stent-Graft

I reported previously (Apr 2018) when Israel’s Endospan received the CE mark for its Horizon stent graft system to treat Abdominal Aortic Aneurysm. It now also has received the CE mark for its Nexus Stent Graft System to treat Aortic … Continue reading →

Israel’s Endospan has received the CE mark for its HORIZON Stent Graft System to treat Abdominal Aortic Aneurysm (AAA). Endospan is also awaiting European approval for its NEXUS™ Stent Graft System to treat Aortic Arch Disease. https://docs.wixstatic.com/ugd/625ec5_ca352c21453446b0ac8a833dd4b5bacb.pdf https://www.endospan.com/